Biogen Inc   (BIIB)
Other Ticker:  
Price: $231.6900 $-2.15 -0.919%
Day's High: $233.71 Week Perf: 2.53 %
Day's Low: $ 230.26 30 Day Perf: -1.54 %
Volume (M): 748 52 Wk High: $ 298.73
Volume (M$): $ 173,258 52 Wk Avg: $243.67
Open: $232.56 52 Wk Low: $189.44

 Market Capitalization (Millions $) 33,804
 Shares Outstanding (Millions) 146
 Employees 9,610
 Revenues (TTM) (Millions $) 9,663
 Net Income (TTM) (Millions $) 1,167
 Cash Flow (TTM) (Millions $) -1,816
 Capital Exp. (TTM) (Millions $) 361

Biogen Inc
Biogen Idec creates new standards of care in oncology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, we transform scientific discoveries into advances in human healthcare. We currently have four commercial products: AVONEX' (Interferon beta-1a) for the treatment of relapsing multiple sclerosis, also known as MS, RITUXAN' (rituximab)'and ZEVALIN' (ibritumomab tiuxetan), both of which treat certain B-cell non-Hodgkin's lymphomas, also referred to as B-cell NHLs, and AMEVIVE' (alefacept)'for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

   Company Address: 225 Binney Street Cambridge 2142 MA
   Company Phone Number: 679-2000   Stock Exchange / Ticker: NASDAQ BIIB

Customers Net Income fell by BIIB's Customers Net Profit Margin fell to

-30.62 %

2.71 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
AMGN   -2%    
ABBV   -1.1%    
ABT   -3.54%    
BMY   -3.22%    
JNJ   -1.08%    
MRK   -1.53%    
• View Complete Report


Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and ...

Published Mon, Jun 10 2024 1:00 AM UTC

Major Law Firms Alert Investors: Class Action Lawsuits Against Biogen, Charge Enterprises, and Fastly??Deadlines LoomingNew York, June 9, 2024 ?? Bragar Eagel & Squire, P.C., a nationally-recognized shareholder rights law firm, has formally reminded investors that class action lawsuits have been filed against three prominent corporations: Biogen Inc. (NASDAQ: BIIB), Charge ...

Product Service News

FDA Accepts Eisais Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance D...

Published Sun, Jun 9 2024 11:38 PM UTC

'FDA Accepts Eisai's sBLA for LEQEMBI IV Maintenance Dosing Amidst Biogen's Market Challenges''TOKYO and CAMBRIDGE, Mass., June 9, 2024' - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai) and Biogen Inc. (Nasdaq: BIIB, Corporate Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher) today announced that the U.S. Food and Drug Administration (F...


Biogen Inc. Faces Class Action Lawsuit and Revenue Decline Amidst Challenging Market Conditions

Published Wed, Jun 5 2024 2:37 PM UTC

Biogen Inc., a leading biopharmaceutical company, is currently facing a class action lawsuit and a decline in revenue. The company and certain officers have been named as defendants in the lawsuit, which was filed in the United States District Court for the District of Colorado. Shareholders who suffered losses on their investments in Biogen Inc. between February 3, 2022, an...


Enhancing Accessible Air Travel: Biogens Collaboration with Delta Flight Products and Financial Insights for Q...

Published Mon, Jun 3 2024 11:30 AM UTC

'Abstract:'This article outlines the collaboration between Biogen Inc. and Delta Flight Products to enhance air travel accessibility for passengers with reduced mobility. Additionally, it examines Biogen's financial performance in Q1 2024, highlighting trends in revenue, costs, and corporate customer performance.''On June 3, 2024, Biogen Inc. (Nasdaq: BIIB) and Delta Flight ...

Clinical Study

Biogen Unlocks the Genetic Code: A Plunge into a New Era of Rare Disease Treatment...

Published Thu, May 30 2024 8:51 PM UTC

In recent developments, Biogen Inc. has made significant strides in the field of drug discovery by receiving European Commission approval for two groundbreaking therapies. The first therapy, QALSODY (tofersen), is the first treatment of its kind in the European Union to target a genetic cause of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND). T...


Biogen Inc's Segments
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Biogen Inc announced annual revenue outlook on

Earnings Outlook
Biogen Inc issued annual earnings guidance on

Geographic Revenue Dispersion
United States


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com